100 results on '"Lamprecht P"'
Search Results
2. AB1245 AVACOPAN IN ANCA-ASSOCIATED VASCULITIS RECEIVED INTENSIFIED INDUCTION THERAPY WITH CYCLOPHOSPHAMIDE PLUS RITUXIMAB – RETROSPECTIVE OBSERVATION TWO-CENTRE STUDY OF 30 PATIENTS
3. AB1263 THE JOINT VASCULITIS REGISTRY IN GERMAN-SPEAKING COUNTRIES (GEVAS) – SUBGROUP ANALYSIS OF 266 AAV-PATIENTS
4. OP0102 IDENTIFICATION OF NEW RISK LOCI AND PATHWAYS INVOLVED IN GCA PATHOGENESIS BY A GENOME-WIDE STUDY
5. POS0875 AUTOANTIBODIES DIRECTED TO G-PROTEIN COUPLED RECEPTORS CORRELATE WITH DISEASE ACTIVITY SCORES IN PATIENTS WITH PSORIATIC ARTHRITIS
6. POS1161 RITUXIMAB VS. COMBINATION OF RITUXIMAB AND CYCLOPHOSPHAMIDE INDUCTION THERAPY FOR ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY
7. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan
8. POS0829 SPECTRUM OF ANCA-SPECIFICITIES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS IN A RETROSPECTIVE MULTICENTER STUDY
9. AB0660 Long-term effect of combination therapy with rituximab and mycophenolic acid on cardiac manifestations, pulmonary function and skin fibrosis in systemic sclerosis
10. POS0800 THE JOINT VASCULITIS REGISTRY IN GERMAN-SPEAKING COUNTRIES (GeVas) – SUBGROUP ANALYSIS OF 131 GCA-PATIENTS REFERENCES
11. AB0622 The Joint Vasculitis Registry in German-speaking countries (GeVas) – subgroup analysis of 113 GPA-patients
12. Der außergewöhnliche Nachahmer einer Polymyositis
13. OP0054 NEW ROLE FOR PROTEINASE 3 IN IL-16 BIOACTIVITY CONTROL IN GRANULOMATOSIS WITH POLYANGIITIS
14. S2k-Leitlinie (Kurzfassung): Management der Großgefäßvaskulitiden
15. S2k-Leitlinie: Management der Großgefäßvaskulitiden
16. THU0025 MICRO-RNA DIFFERENTIALLY REGULATE THE ALTERNATIVE PRTN3-MRNA IN GRANULOMATOSIS WITH POLYANGIITIS
17. FRI0001 NEUTROPHILS IN GRANULOMATOSIS WITH POLYANGIITIS DISPLAY FEATURES OF PYROPTOSIS
18. AB0496 AUTOANTIBODIES TARGETING COMPLEMENT RECEPTORS 3A AND 5A1 ARE DECREASED IN ANCA-ASSOCIATED VASCULITIS AND CORRELATE WITH HIGHER RELAPSE RATE.
19. Pathogenese der Großgefäßvaskulitiden
20. AB0035 A physiological network of igg autoantibodies targeting g protein coupled receptors
21. Nasales Mikrobiom bei Patienten mit Granulomatose mit Polyangiitis
22. Nasal microbiome of patients with granulomatosis with polyangiitis
23. FRI0582 Open-label, multicenter, dose-escalating phase ii clinical trial on the safety and efficacy of tadekinig alpha in adult onset still's disease
24. SP0184 Role of microenvironment and endogenous pathways to break tolerance
25. AB0175 Inhibitory effect of endothelin-1 type a receptor antagonists on migration of neutrophils and tumour cells
26. SAT0011 The activation of muscarinic acetylcholine receptors influences the ontogeny of neutrophils
27. Therapiedeeskalation bei ANCA-assoziierten Vaskulitiden
28. IgG4-assoziierte Erkrankung
29. Klinisches Spektrum der IgG-4-assoziierten Erkrankungen und der Bezug zur Rheumatologie
30. SAT0336 Damage-Associated Molecular Patterns IL-33 and High-Mobility Group Box 1 Amplify Inflammatory Processes in Granulomatosis with Polyangiitis
31. Effektor-Memory-T‑Zellen in der Pathogenese von ANCA-assoziierten Vaskulitiden
32. Effector memory T‑cells in the pathogenesis of ANCA-associated vasculitides
33. Vaskulitiden
34. SP0199 How To Treat / Manage: Vasculitis
35. Kognition und mikrostrukturelle Veränderungen bei Patienten mit hepatischer Encephalopathie vor TIPS-Anlage: eine MR- (VBM, TBSS) und neuropsychologische Studie
36. AB0734 Prevalence and co-occurrence of autoantibodies in blood donors
37. THU0214 Treatment of refractory giant cell arteritis with cyclophosphamide. A retrospective analysis of 35 patients from three tertiary care centers
38. Systemische Vaskulitiden: Revidierte Nomenklatur, neue Therapiestrategien
39. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
40. Revidierte Chapel-Hill-Nomenklatur der Vaskulitiden
41. How I treat …
42. Autoinflammation
43. T-Zellen bei ANCA-assoziierten Vaskulitiden
44. Molecular signatures of a disturbed nasal barrier function in the primary tissue of Wegener's granulomatosis
45. Preliminary classification criteria for the cryoglobulinaemic vasculitis
46. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis
47. Untersuchungen über die NNR-Funktion bei landwirtschaftlichen Nutztieren mit Hilfe der Cortisol- und Corticosteronbestimmung nach dem Prinzip der konkurrierenden Eiweißbindungsanalyse
48. Adulter Morbus Still, Schnitzler-Syndrom und autoinflammatorische Syndrome im Erwachsenenalter
49. Autoinflammation und Inflammation
50. Olfactory dysfunction in Wegener's granulomatosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.